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Chronic Myeloprolife ra tive  Syndromes
Introduction
Myelofibrosis has the worst median overall survival of the
BCR-ABL–negative myeloproliferative neoplasms and can
present as primary disease or evolve from polycythemia vera
or essential thrombocythemia.1 Regardless of its origin,
myelofibrosis is characterized by bone marrow fibrosis, pro-
gressive splenomegaly, cytopenias and burdensome debilitat-
ing constitutional symptoms,2 leading to a severely dimin-
ished quality of life (QoL).3 The median survival of patients
w ith myelofibrosis ranges from 2 to 11 years, depending on
defined prognostic factors.4
Treatment options for myelofibrosis have generally been
palliative w ithout impact on the natural history of the dis-
ease. Although stem cell transplant is a potentially curative
treatment for patients w ith myelofibrosis, it is an option for
only a minority of patients, and the rates of mortality and
treatment-related toxicities and complications remain high.5
However, the recent identification of aberrant activation of
the Janus kinase (JAK) signaling pathw ay – along w ith an
improved understanding that cytokines that signal through
JAK1 and JAK2 play a role in the development of myelopro-
liferative neoplasms – has led to the development of new
therapeutic approaches.6-9
Ruxolitinib (also known as INC424 and INCB018424) is a
potent and selective inhibitor of JAK1 and JAK2. It was
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Prior to Janus kinase inhibitors, available therapies for myelofibrosis were generally supportive and did not
improve survival. This analysis compares efficacy outcomes of patients w ith myelofibrosis in the control arms
(placebo [n=154] and best available therapy [n=73]) from the two phase 3 COntrolled MyeloFibrosis study with
ORal JAK inhibitor Treatment (COMFORT) studies. Spleen volume w as assessed by magnetic resonance imag-
ing/computed tomography at baseline and every 12 weeks through w eek 72; spleen length was assessed by pal-
pation at each study visit. Health-related quality of life and symptoms were assessed using the European
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items at baseline and
in weeks 4, 8, 12, 16 and 24 in COMFORT-I and in weeks 8, 16, 24 and 48 in COMFORT-II. The demographic
and baseline characteristics w ere similar betw een the control arms of the two studies. One patient who received
placebo and no patients who received best available therapy had a ≥35%  reduction in spleen volume from baseline
at w eek 24. At 24 w eeks, neither placebo nor best available therapy had produced clinically meaningful changes
in global quality of life or symptom scales. Non-hematologic adverse events were mostly grade 1/2; the most fre-
quently reported adverse events in each group were abdominal pain, fatigue, peripheral edema and diarrhea.
These data suggest that non–Janus kinase inhibitor therapies provide little improvement in splenomegaly, symp-
toms or quality of life as compared with placebo. Both COMFORT-I (NCT00952289) and COMFORT-II
(NCT00934544) studies have been appropriately registered with clinicaltrials.gov.
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approved in November 2011 by the US Food and Drug
Administration for the treatment of intermediate- or high-
risk myelofibrosis10 and more recently by Health Canada11
and the European Commission for the treatment of
myelofibrosis-related splenomegaly or symptoms.12
Ruxolitinib was approved based on data from two pivotal
phase 3 COntrolled MyeloFibrosis study with ORal JAK
inhibitor Treatment (COMFORT) trials:13,14 COMFORT-I
was double-blind and placebo-controlled and COMFORT-
II w as an open-label study that compared ruxolitinib w ith
best available therapy (BAT). In both studies, patients who
received ruxolitinib had rapid and durable reductions in
splenomegaly and improvements in disease-related symp-
toms, role functioning and QoL measures. In contrast,
patients in the control arms of both of these studies gener-
ally had increases in splenomegaly and w orsening of
symptoms, demonstrating that non–JAK inhibitor treat-
ments w ere not efficacious. Here, we present a post hoc
analysis specifically evaluating the efficacy outcomes and
safety of the placebo arm of COMFORT-I compared w ith
those of the BAT arm of COMFORT-II.
Methods
Patients, study design and treatment
COMFORT-I w as a randomized (1:1), double-blind,
multicenter study that compared the safety and efficacy of
ruxolitinib 15 or 20 mg tw ice daily (n=155) w ith placebo
(n=154) in patients w ith primary myelofibrosis, post-poly-
cythemia vera myelofibrosis or post-essential thrombo-
cythemia myelofibrosis.13 COMFORT-II was a random-
ized (2:1), open-label, multicenter study that compared
ruxolitinib 15 or 20 mg tw ice daily (n=146) w ith BAT
(n=73) in patients w ith patients w ith primary myelofibro-
sis, post-polycythemia vera myelofibrosis or post-essen-
tial thrombocythemia myelofibrosis.14 The choice of dose
of ruxolitinib (15 or 20 mg tw ice daily) was based on
platelet count at baseline (100-200 or >200x109/L, respec-
tively). Eligibility criteria were previously reported else-
w here.13,14 BAT included any commercially available
agents (as monotherapy or in combination) or no therapy
at all and could be changed during the treatment phase
(Table 1).14 Crossover was permitted in each study accord-
ing to the protocol-specified criteria previously
described.13,14 The COMFORT-I and COMFORT-II studies
were approved by the institutional review  boards of the
respective institutions and conducted in accordance w ith
the principles of the Declaration of Helsinki. All patients
provided written informed consent.  
Assessments
As previously described, the analysis for this study was
conducted w hen all enrolled patients completed week 24
for COMFORT-I (data cut-off date, November 2, 2010)13
or w eek 48 for COMFORT-II (data cut-off date, January 4,
2011)14 or were w ithdrawn from the study. The primary
end-point was a reduction of ≥35%  in spleen volume from
baseline at w eek 24 and week 48 for COMFORT-I and
COMFORT-II, respectively. COMFORT-II had a key sec-
ondary end-point (type I error controlled) of reduction of
≥35%  in spleen volume from baseline at week 24. Spleen
volume was assessed by magnetic resonance imaging
(MRI) or computed tomography (CT; in those patients
who were not candidates for MRI) every 12 w eeks up to
week 72. In COMFORT-I, any patient w ho crossed over
before w eek 24 or discontinued from the study was count-
ed as a non-responder for response measures of reduction
in spleen volume and symptom improvement. In COM-
FORT-II, any patient who discontinued from the study or
had a protocol-defined event of disease progression14
before week 48 w as considered to be a non-responder.
Spleen length was assessed by manual palpation at every
study visit.
Health-related QoL and symptoms were assessed using
the European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire-Core 30 Items
(EORTC QLQ-C30), w hich w as completed by patients at
baseline in both studies, in weeks 4, 8, 12, 16 and 24 in
COMFORT-I and in weeks 8, 16, 24 and 48 in COM-
FORT-II. The EORTC QLQ-C30 includes five functional
scales (physical, role, emotional, cognitive and social func-
tioning), a global health status/QoL scale and nine symp-
tom scales (fatigue, nausea and vomiting, pain, dyspnea,
insomnia, appetite loss, constipation, diarrhea and finan-
cial difficulties). All scores range from 0 to 100. For func-
tional and global health status/QoL scales, higher scores
indicate better QoL; for symptom scales, higher scores
indicate more severe symptoms. For the EORTC QLQ-
C30 global health status/QoL scale, patients w ith a 10%
(or 10-point) improvement in score w ere considered to
have clinically meaningful improvements.15
Results
In the COMFORT-I and COMFORT-II studies, 154
patients received placebo and 73 patients received BAT,
respectively, and all were included in the primary efficacy
analyses except for one patient in each group with a miss-
ing baseline spleen volume assessment. Among those w ho
were randomized to BAT, 49 patients (67% ) received any
BAT medication – referred to hereafter as BAT-treated –
and 24 patients (33% ) received no therapy as BAT during
the randomized treatment phase. As previously described
by Harrison et al.,14 of the 49 BAT-treated patients, 37
patients (76% ) w ere given antineoplastic agents, most
commonly hydroxyurea (n=32; 65% ), and 12 patients
(24% ) were given glucocorticoids. The demographic and
baseline characteristics w ere generally similar betw een
the control arms of the tw o studies (Table 2), including
Placebo vs . BAT in the  COMFORT s tudies
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Table 1. Patients’ treatments on the BAT-treated arm.14
Agent                                                                         BAT, n. (%)
                                                                                     (n=73)
Antineoplastic agents                                                               37 (51)
Hydroxyurea                                                                               34 (47)
Glucocorticoids                                                                         12 (16)
Epoetin alfa                                                                                  5 (7)
Immunomodulators                                                                    5 (7)
Purine analogues                                                                        4 (5)
Androgens                                                                                     3 (4)
Interferons                                                                                   3 (4)
Nitrogen mustard analogues                                                    2 (3)
Pyrimidine analogues                                                                 2 (3)




spleen length below the costal margin: median, 16.0 cm
(range, 5.0-34.0) and 15.0 cm (range, 5.0-37.0) in the place-
bo and BAT arms, respectively. Compared w ith patients
who received BAT, those who received placebo were
older and higher proportions had high-risk disease and
were JAK2 V617F-positive and hydroxyurea-naïve.
Overall, 52%  of patients receiving placebo and 42%  of
patients receiving BAT (35%  BAT-treated) w ere ongoing
in the randomized treatment phase at the data cut-off date
(Table 3). Of those who discontinued the study, a similar
proportion of patients in each group crossed over to
receive ruxolitinib [placebo, 36 of 151 (24% ); BAT, 18 of
73 (25% ; of whom 12 of 18 (67% ) w ere BAT-treated)].
Efficacy
Spleen size
As shown in Figure 1, only one patient (0.7% ) w ho
received placebo and no patients who received BAT
achieved a ≥35%  reduction in spleen volume from base-
line at week 24 (the primary end-point of COMFORT-I
and the key secondary end-point of COMFORT-II). The
patient in the placebo arm who achieved this reduction in
spleen volume died from disease progression 4 days later,
possibly from splenic infarction.16 During the 24-w eek
period, the majority of patients treated w ith placebo
(75% ) or BAT (69% ) had measurable increases in spleen
volume. Of those patients in the BAT group, a similar pro-
Table 2. Patients’ demographic and baseline characteristics.
COMFORT-I COMFORT-II
Placebo BAT BAT treated
(n=154) (n=73) (n=49)
Age, median (range), year 70 (40-86) 66 (35-85) 67 (46-85)
Male, n. (%) 88 (57) 42 (58) 29 (59)
Myelofibrosis type, n. (%)
PMF 84 (55) 39 (53) 25 (51)
PPV-MF 47 (31) 20 (27) 16 (33)
PET-MF 22 (14) 14 (19) 8 (16)
High/intermediate-2 99 (64)/54 (35) 43 (59)/29 (40) 28 (57)/21 (43)
IPSS risk, n. (%)
JAK2V617F positive, n. (%) 123 (80) 49 (67) 36 (73)
Palpable spleen size 16.0 (5.0-34.0) 15.0 (5.0-37.0) 16.5 (6.0-37.0)
below costal margin, median
(range), cm
Spleen volume,* median 2566.3 2317.9 2482
(range), cm3 (521.0-8880.7) (728.5-7701.1) (728.5-7701.1)
Prior HU therapy, n. (%) 87 (56) 50 (68) 43 (88)
COMFORT: controlled myelofibrosis study with oral JAK inhibitor treatment; BAT: best available
therapy; PMF: primary myelofibrosis; PPV-MF: post–polycythemia vera myelofibrosis; PET-MF:
post–essential thrombocythemia myelofibrosis; IPSS: International Prognostic Scoring System;
JAK2: Janus kinase 2; HU: hydroxyurea. *Normal spleen volume is 150 to 200 cm3.
Table 3. Patients’ disposition.
                                                            COMFORT-I COMFORT-II
Patients, n. (%)                                      Placebo              BAT           BAT treated
                                                             (n=151)*            (n=73)             (n=49)
Ongoing in randomized                                 78 (52)                31 (42)                17 (35)
treatment phase
Crossed over to ruxolitinib**                      36 (24)                18 (25)                12 (24)
Discontinued                                                   37 (25)                24 (33)                20 (41)
Disease progression                                    12 (8)                   3 (4)                    3 (6)
Death                                                                 9 (6)                    0***                    0***
Adverse event(s)                                            8 (5)                    4 (5)                    4 (8)
Consent withdrawn                                        5 (3)                   9 (12)                  7 (14)
Other                                                                 3 (2)              7 (10)****             5 (10)
Non-compliance with study procedure        0                       1 (1)                    1 (2)
COMFORT: controlled myelofibrosis study with oral JAK inhibitor treatment; BAT: best available
therapy. *The other three patients were not evaluable for safety but were included in the intention-
to-treat analysis of efficacy. * *According to protocol-defined criteria for crossover. * * * Deaths were
not reported as a reason for discontinuation in COMFORT-II. However, there were four deaths in
the BAT group; all four patients were BAT-treated and were counted in different reasons for discon-
tinuation. * * * * Included investigator decision, splenectomy, treatment failure, poor patient condi-
tion, refusal of follow-up, bone marrow transplant and thrombocytopenic event confirming disease
progression (1 each).
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Figure 1. Percent change from baseline in
spleen volume as assessed by magnetic res-
onance imaging/ computed tomography at
week 24 for patients with baseline and ≥1






























portion of BAT-treated patients [18 of 26 (69% )] and of
those who received no BAT medications (13 of 19 [68% ])
had spleen volume increases.
The mean percentage change in spleen volume over
time increased in the control groups of both studies and,
in general, these increases were observed by the first
assessment (12 w eeks; Figure 2A). Changes in palpable
spleen length in both groups mirrored the increases in
spleen volume assessed by MRI/CT (Figure 2B). Although
treatment in the BAT group was not blinded to the
patients, all scans were read by a central blinded reader
and, in general, similar increases in spleen volume
assessed by MRI/CT were observed between the overall
BAT and BAT-treated groups over time. With palpable
spleen length, in w hich measurements were not blinded,
some differences in the mean percentage change in spleen
length over time between the BAT-treated and overall BAT
populations w ere observed, w ith an apparent tendency
tow ard smaller changes.
Symptoms and other patient-reported outcomes
At week 24, patients in the placebo arm and BAT arms
did not have clinically meaningful improvements from
baseline in any of the health-related QoL (Figure 3) or
symptom scores (Figure 4), w hereas the BAT-treated sub-
group had a clinically meaningful improvement in global
health status/QoL. Patients in each of the control groups
had worsening from baseline in role functioning, w hich
was clinically significant for the placebo group at week 24.
Additionally, regardless of the control group, patients gen-
erally had w orsening of myelofibrosis-associated symp-
toms, including appetite loss, dyspnea, insomnia and pain.
In particular, worsening of appetite loss and dyspnea w as
observed in BAT-treated patients, and w orsening of pain
was noted in placebo patients. Although scores for insom-
nia showed some improvements w ith placebo and scores
for pain and fatigue showed improvements in BAT-treated
patients, no clinically meaningful improvements w ere
observed in either group.
Safety
As shown in Table 4, patients who received placebo gen-
erally reported higher rates of the most frequent non-hema-
tologic adverse events. Events that occurred with approxi-
mately ≥10%  higher incidence in the placebo arm than in
the BAT arm were abdominal pain (41%  with placebo ver-
sus14%  with BAT), fatigue (34%  versus8% ), diarrhea (21%
versus12% ) and nausea (19%  versus7% ). Peripheral edema
was the most frequently reported adverse event in the BAT
group (26% ) and was also reported at a similar rate in the
Placebo vs . BAT in the  COMFORT s tudies
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Figure 2. Mean per-
centage change from
baseline in (A) spleen





over time. BAT: best
available therapy.
Figure 3. Mean change from baseline
to week 24 in European Organisation
for Research and Treatment of
Cancer (EORTC) Quality of Life (QoL)
Questionnaire-Core 30 Items (QLQ-
C30) scores. Only patients with meas-
urements at both baseline and week
24 were included. EORTC QLQ-C30
global health status/ QoL and func-
tioning scales range from 0 to 100,
with higher scores indicating better
health-related QoL. A clinically mean-
ingful treatment difference was
defined as a 10-point improvement or
10-point worsening from baseline for
global health status/ QoL. BAT: best
available therapy.
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n=154 132 106 46 13
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placebo group (23% ). There were no events that occurred
with a ≥10%  higher incidence in the BAT arm than in the
placebo arm; cough and nasopharyngitis were reported at a
≥5%  higher incidence in patients who received BAT com-
pared with those who received placebo. When BAT-treated
patients were considered, peripheral edema, cough and
asthenia were reported at a ≥5%  higher rate than in patients
who received placebo. In general, the rates of grade 3/4
adverse events were similar between the control arms,
although rates of abdominal pain (11%  with placebo versus
3%  with BAT) and fatigue (7%  versus 0% ) were higher in
the placebo arm than in the BAT arm. Of the most common
grade 3/4 events reported in the BAT arm of COMFORT-II,
all but one (a case of dyspnea) occurred in BAT-treated
patients.
Discussion
More than 130 years after the first description of
myelofibrosis by Heuck in 1879,17 the treatment of
patients w ith this condition has remained mostly support-
ive and the natural progression of myelofibrosis has not
been significantly improved by drug therapy.18 In both of
R.A. Mes a  e t a l.
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Table 4. Non-hematologic adverse events regardless of study drug relationship (≥10% in any group).
COMFORT-I COMFORT-II 
Placebo (n=151)* BAT (n=73)** BAT treated (n=49)**
Adverse event All grades, n. (%) Grade 3/ 4, n. (%) All grades, n. (%) Grade 3/ 4, n. (%) All grades, n. (%) Grade 3/ 4, n. (%)
Abdominal pain 62 (41) 17 (11) 10 (14) 2 (3) 6 (12) 2 (4)
Fatigue 51 (34) 10 (7) 6 (8) 0 4 (8) 0
Peripheral edema 34 (23) 2 (1) 19 (26) 0 14 (29) 0
Diarrhea 32 (21) 0 9 (12) 0 6 (12) 0
Nausea 29 (19) 1 (1) 5 (7) 0 5 (10) 0
Dyspnea 26 (17) 6 (4) 13 (18) 3 (4) 8 (16) 2 (4)
Cough 13 (9) 0 11 (15) 1 (1) 7 (14) 1 (2)
Pruritus 23 (15) 2 (1) 9 (12) 0 5 (10) 0
Nasopharyngitis 9 (6) 0 10 (14) 0 5 (10) 0
Constipation 18 (12) 0 4 (5) 0 3 (6) 0
Night sweats 18 (12) 2 (1) 6 (8) 0 3 (6) 0
Back pain 12 (8) 1 (1) 8 (11) 0 4 (8) 0
Asthenia 12 (8) 4 (3) 7 (10) 1 (1) 7 (14) 1 (2)
Insomnia 15 (10) 0 5 (7) 0 4 (8) 0
Pain in extremity 15 (10) 0 3 (4) 0 3 (6) 0
Pyrexia 11 (7) 1 (1) 7 (10) 0 4 (8) 0
Vomiting 15 (10) 1 (1) 1 (1) 0 1 (2) 0
COMFORT: controlled myelofibrosis study with oral JAK inhibitor treatment; BAT: best available therapy.*Median 32.2 weeks of follow-up.* *Median 50.1 weeks of follow-up.
Figure 4. Mean change from baseline
to week 24 in select European
Organisation for Research and
Treatment of Cancer (EORTC) Quality of
Life (QoL) Questionnaire Core 30 Items
(QLQ-C30) scores. EORTC QLQ-C30
symptom scales range from 0 to 100,
with higher scores indicating worse
symptoms. BAT: best available therapy.
* n=105. * * n=38. * * * n=104.
Placebo (n= 107)
BAT (n= 39)
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the COMFORT studies, it was demonstrated that signifi-
cantly more patients who received ruxolitinib had rapid
and durable reductions in splenomegaly as w ell as
improvements in symptoms and QoL compared w ith
patients in the control arms, and that these reductions
were maintained throughout each study period.13,14 The
lack of efficacy w ith non–JAK inhibitor therapeutics in
COMFORT-II is of the utmost relevance because conclu-
sions from previous studies of therapeutics in patients
with myelofibrosis have been hampered by small num-
bers and the lack of objective response criteria and a con-
trol arm.19-22 For example, one retrospective study showed
that the use of hydroxyurea, w hich was the most com-
mon treatment in the BAT arm, resulted in a 40%  rate of
clinical improvement by International Working Group-
Myeloproliferative Neoplasms Research and Treatment
(IWG-MRT) criteria, w ith improvements in splenomegaly,
symptoms and blood counts.20 However, this study only
included 40 patients, and the subgroups evaluated were
small, w ith 18 patients evaluable for spleen size and 22
patients evaluable for constitutional symptoms; in addi-
tion, the lack of a control arm makes the reported response
rates difficult to interpret.
We acknowledge that a direct side-by-side comparison
would be ideal to assess the efficacy of BAT compared
with placebo and recognize that the data presented here
are inevitably limited because they are derived from tw o
different studies. However, although there are some dif-
ferences in the patient populations and eligibility and
inclusion criteria of the COMFORT-I and COMFORT-II
studies, the general similarities in the trial end-points, peri-
od of accrual and responses achieved w ith ruxolitinib in
each of the studies allow  for some meaningful compar-
isons. In this post hoc analysis, patients who received BAT
had numerically similar increases in spleen size as those
w ho received placebo, and no clinically meaningful
improvements in QoL or symptoms were seen in either
the placebo or BAT arm. These data suggest that non–JAK
inhibitor treatments for myelofibrosis provide little
improvement in spleen size, symptoms or health-related
QoL compared w ith placebo. Although it is conceivable
that some patients in the BAT arm of COMFORT-II were
not sufficiently aggressively treated, this is unlikely as evi-
denced by the observation that some patients had spleen
regression and that anemia and transfusion rates were
equivalent across the tw o arms of COMFORT-II.
Whereas COMFORT-I w as a double-blind, placebo-
controlled study, COMFORT-II was an open-label study
in w hich treatment in the BAT arm was based on physi-
cians’ choice and could, therefore, include any single treat-
ment or combination of treatments, including any
sequence of treatments or no treatment (i.e. “w atchful
waiting”). Based on these options, approximately one-
third of the patients in the BAT arm received no
treatment.14 To account for this possible confounding fac-
tor, the efficacy and safety data of the 49 patients (67% )
who received any BAT medication w ere evaluated as a
separate subgroup. A similarly low  proportion of patients
who received BAT medications had reductions in spleen
volume as assessed by MRI/CT compared w ith those w ho
did not receive any BAT medication. The increases in
spleen volume in the BAT-treated and overall BAT groups
also mirrored those observed w ith placebo, suggesting
that non–JAK inhibitor therapies do not have any signifi-
cant effect on spleen size.
The symptomatic burden of patients is an important
clinical feature of myelofibrosis because these debilitating
symptoms contribute to a diminished QoL and interfere
w ith activities of daily living.3 At 24 w eeks, neither
patients in the placebo arm nor those in the BAT arm had
clinically meaningful improvements from baseline in any
of the QoL or symptom scores. Patients in the placebo
group had a clinically significant w orsening in role func-
tioning from baseline at w eek 24. Although BAT-treated
patients show ed a clinically meaningful improvement in
global health status/QoL, these patients did not have sig-
nificant improvements in role functioning or in any
myelofibrosis-associated symptom and, in fact, had sig-
nificant w orsening of appetite loss and dyspnea at w eek
24. These data confirm those reported by Mesa et al.3 in
w hich patients reported having a significant burden of
disease-related symptoms, even though the majority
received one or more non–JAK inhibitor treatment. Thus,
even w ith the flexibility of therapeutic options in the BAT
arm, non–JAK inhibitor treatments w ere inadequate at
controlling patients’ symptoms and QoL, just as w as
placebo. This inadequacy highlights the natural progres-
sion of myelofibrosis in these patients, even over the
short 24-w eek study period. Although it is interesting to
compare the control arms of the COMFORT trials to
illustrate the unmet need of patients treated w ith BAT, it
is important to note that the outcomes of patients in both
the placebo and BAT arms w ere significantly inferior to
those of the ruxolitinib-treated patients in both studies.13,14
In summary, patients who received BAT in COMFORT-
II appeared to fare no better than patients who received
placebo in COMFORT-I, and these findings illustrate that
conventional therapeutic alternatives for patients w ith
myelofibrosis do not alleviate the symptom burden of the
disease in a meaningful w ay, underscoring the need for
better treatments. The clinical success of JAK1/2
inhibitors, including the superiority of ruxolitinib in the
COMFORT studies,13,14 indicates that JAK inhibitor thera-
py for myelofibrosis  provides a valuable and effective
new  treatment option for patients.
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